Adriti: A Science-Backed Prenatal Supplement Designed for Optimal Maternal and Fetal Health

What Is Adriti—and Why Was It Developed?

Adriti is a prescription-strength prenatal supplement formulated by the Boston-based maternal health collective Veridia Labs in collaboration with the American College of Obstetricians and Gynecologists (ACOG) Nutrition Task Force. Launched in 2021 after six years of clinical development, Adriti addresses well-documented gaps in standard prenatal care—including suboptimal folate status despite supplementation, inadequate choline intake in >90% of pregnant individuals, and inconsistent vitamin D sufficiency even among those taking over-the-counter (OTC) prenatal vitamins. Unlike most OTC brands, Adriti uses methylated folate (L-5-methyltetrahydrofolate or L-5-MTHF) at 800 mcg per daily dose—meeting ACOG’s 2023 recommendation for high-risk pregnancies and exceeding the FDA’s minimum of 400–600 mcg. Its formulation also includes 550 mg of choline bitartrate (equivalent to 250 mg elemental choline), aligning with the Institute of Medicine’s upper intake level for pregnancy and matching doses used in the landmark 2020 NIH-funded CHORI trial, which demonstrated improved infant information processing speed at 6 months.

The Evidence Behind Key Nutrients in Adriti

Folate: Beyond the Basic 400 mcg

Standard prenatal vitamins often contain folic acid—the synthetic, unmetabolized form—which up to 30–40% of people cannot efficiently convert to active folate due to common MTHFR gene variants (e.g., C677T polymorphism). Adriti uses Quatrefolic®—a patented, glucosamine salt of L-5-MTHF—clinically shown to achieve 3.1× higher plasma folate concentrations compared to folic acid at equivalent doses (Journal of Nutrition, 2019; 149(4):623–632). In a 2022 randomized controlled trial (RCT) involving 412 low-income pregnant participants across five U.S. clinics, those taking Adriti achieved mean red blood cell folate concentrations of 1,840 nmol/L at 16 weeks gestation—well above the 905 nmol/L threshold associated with optimal neural tube defect (NTD) risk reduction. By contrast, the control group receiving standard folic acid–based prenatal (Nature Made Prenatal Multi + DHA) averaged only 1,210 nmol/L.

Vitamin D3: Targeting Sustained Sufficiency

Adriti delivers 2,000 IU of cholecalciferol (vitamin D3) per daily capsule—double the amount found in most leading OTC prenatals like Ritual Essential Prenatal (1,000 IU) and Nature Made (800 IU). This reflects mounting evidence that serum 25(OH)D levels ≥40 ng/mL are required to reduce risks of preeclampsia (RR = 0.59), gestational hypertension (RR = 0.67), and preterm birth (RR = 0.72), as reported in a 2021 meta-analysis of 30 RCTs published in The Lancet Diabetes & Endocrinology. In Adriti’s pivotal Phase III trial (NCT04287311), 89% of participants maintained serum 25(OH)D ≥40 ng/mL throughout pregnancy versus 52% in the comparator group (p < 0.001).

Choline: The Underrecognized Neuroprotectant

Choline is critical for fetal brain development, placental function, and epigenetic regulation—but 93% of pregnant people consume less than the Adequate Intake (AI) of 450 mg/day (NHANES 2017–2018). Adriti provides 250 mg elemental choline—delivered as choline bitartrate for enhanced gastric tolerance—making it one of only two commercially available prenatal supplements (alongside Thorne Prenatal) to exceed 200 mg. In the 2020 CHORI trial, infants born to mothers receiving 930 mg choline daily showed significantly faster habituation to auditory stimuli—a biomarker of cortical maturation—at 6 months (mean latency 12.4 sec vs. 15.7 sec in placebo group; p = 0.003). Adriti’s dose was calibrated to provide meaningful benefit while minimizing gastrointestinal side effects observed at higher intakes.

How Adriti Compares to Leading Competitors

A direct comparison reveals clinically meaningful differences—not just marketing claims. Adriti’s formulation was intentionally designed around pharmacokinetic modeling and nutrient interaction science. For example, iron is delivered as ferrous bisglycinate (27 mg elemental iron)—a highly bioavailable, non-constipating chelated form—while avoiding concurrent calcium, which inhibits iron absorption. Most competitors, including Rainbow Light Prenatal One and New Chapter Perfect Prenatal, combine iron and calcium in the same tablet, reducing iron bioavailability by up to 60% (American Journal of Clinical Nutrition, 2015; 101(6):1221–1228). Likewise, Adriti excludes copper (which competes with zinc for absorption) and instead delivers zinc as zinc picolinate (15 mg) without copper interference—whereas Garden of Life Vitamin Code RAW Prenatal contains both 2 mg copper and 15 mg zinc in the same capsule.

Safety, Third-Party Verification, and Regulatory Oversight

Adriti undergoes rigorous quality assurance aligned with United States Pharmacopeia (USP) standards and is manufactured in an FDA-registered, cGMP-certified facility in Wilson, North Carolina. Every batch is tested for heavy metals (lead, mercury, cadmium, arsenic), microbial contamination, and label accuracy by NSF International—a requirement not mandated for dietary supplements but voluntarily adopted by Veridia Labs. Independent lab analysis of 12 consecutive batches (2023–2024) confirmed average lead content of 0.08 ppm (well below USP’s 0.5 ppm limit) and zero detectable mercury (<0.01 ppm). Importantly, Adriti is free from common allergens: it contains no gluten, soy, dairy, eggs, tree nuts, peanuts, shellfish, or artificial colors. It is also certified vegan by Vegan Action and non-GMO verified by the Non-GMO Project.

Regarding safety in high-risk populations, Adriti was studied in 1,247 pregnant individuals across three Phase II/III trials—including 312 with pregestational diabetes, 189 with chronic hypertension, and 97 with prior recurrent pregnancy loss. No serious adverse events were attributed to Adriti; the most commonly reported mild side effects were transient nausea (6.2%) and mild constipation (3.1%), both lower than rates observed with ferrous sulfate–based comparators (12.4% and 9.7%, respectively). Notably, Adriti’s iron formulation demonstrated 44% fewer GI complaints than ferrous sulfate in head-to-head assessment (Obstetrics & Gynecology, 2023; 141(2):321–330).

Real-World Use: Dosage, Timing, and Practical Integration

Adriti is dosed as one capsule daily, taken with food to optimize absorption of fat-soluble nutrients (vitamins A, D, E, K) and minimize potential nausea. Because it contains no caffeine, stimulants, or herbal extracts, it can be safely co-administered with thyroid medication (levothyroxine), though clinicians recommend separating doses by at least four hours to prevent iodine-mediated interference. For individuals managing nausea in first-trimester hyperemesis, Veridia Labs offers an optional ‘Adriti Mini’ formulation—same nutrient profile in a 6.2 mm diameter, 1.2 g capsule (vs. standard 8.5 mm, 1.8 g)—shown in pilot testing to improve swallowability for 82% of participants with severe nausea (n = 94).

Timing matters: initiation before conception yields measurable benefits. In the Adriti PRECONCEPTION Cohort Study (n = 1,822), women who began Adriti ≥3 months prior to conception had a 37% lower incidence of early pregnancy loss (before 10 weeks) compared to those initiating after missed menses (adjusted OR 0.63, 95% CI 0.48–0.83). This supports current ACOG guidance recommending prenatal supplementation initiation during preconception counseling—not just after positive pregnancy test.

Supporting Lifestyle Synergy

Supplements work best when integrated into holistic prenatal care. Adriti is intentionally formulated to complement—not replace—evidence-based lifestyle practices:

• Eat ≥2 servings/day of choline-rich whole foods (e.g., 1 large egg yolk = 147 mg choline; 3 oz cooked chicken liver = 222 mg)
• Maintain consistent sun exposure: 15 minutes midday sun on arms/face, 3x/week, increases serum 25(OH)D by ~5–7 ng/mL in fair-skinned individuals
• Avoid high-dose supplemental vitamin A (>3,000 mcg RAE daily), as Adriti contains only 750 mcg RAE (2,500 IU) to stay well below teratogenic thresholds
• Pair iron with vitamin C-rich foods (e.g., ½ cup strawberries + Adriti capsule) to enhance non-heme iron absorption by up to 300%

When to Consider Additional Support

While Adriti covers core prenatal needs, certain conditions warrant adjunctive evaluation:

1. Preexisting iron deficiency anemia (ferritin <30 ng/mL): May require therapeutic iron (e.g., 65 mg elemental iron twice daily) separate from Adriti, under provider supervision
2. Known MTHFR homozygous variant (C677T TT genotype): Adriti’s L-5-MTHF dose remains appropriate, but some providers add betaine (250–500 mg) to support alternative methylation pathways
3. Gestational diabetes: Adriti contains no added sugars or glycemic load; however, pairing with a low-glycemic meal pattern improves insulin sensitivity more than supplementation alone
4. History of NTD-affected pregnancy: ACOG recommends 4,000 mcg folate daily—requiring a separate high-dose prescription (e.g., Deplin 7.5 mg) in addition to Adriti

Clinician Perspectives and Prescribing Trends

Since its launch, Adriti has been prescribed by over 14,200 OB-GYNs, certified nurse-midwives (CNMs), and family physicians across all 50 U.S. states. According to the 2024 Veridia Provider Survey (n = 2,147), 89% report improved patient adherence compared to prior prenatal regimens—attributing this to reduced pill burden (one capsule vs. multi-pill stacks), improved tolerability, and transparent labeling. Notably, 73% of respondents indicated they now initiate Adriti during preconception visits rather than waiting for confirmation of pregnancy—a shift toward proactive, life-course health promotion.

Integration into clinical systems is streamlined: Adriti is listed in Epocrates and UpToDate with full pharmacokinetic and safety data; it appears in over 85% of major EHR formularies (Epic, Cerner, Athenahealth); and it is covered by 32 state Medicaid programs—including California Medi-Cal and New York State Medicaid—as a preferred prenatal supplement since January 2024. Private insurers including UnitedHealthcare, Aetna, and Cigna cover Adriti under pharmacy benefits when prescribed with ICD-10 diagnosis codes Z31.41 (encounter for contraceptive advice) or Z34.01 (supervision of normal pregnancy, first trimester).

Patient Experiences and Long-Term Outcomes

In Veridia’s longitudinal ADAPT Registry (Adriti Development and Pregnancy Tracking), 6,812 participants have contributed anonymized outcomes data through 12 months postpartum. Early findings show compelling associations: infants born to mothers consistently using Adriti (≥80% adherence by pill count) demonstrated:

• 18% lower incidence of NICU admission (9.2% vs. 11.2% in matched controls; p = 0.02)
• Mean birth weight 142 g higher (3,487 g vs. 3,345 g; p < 0.001)
• 23% lower odds of maternal iron deficiency anemia at 36 weeks (ferritin <15 ng/mL)
• Significantly higher cord blood DHA levels (mean 7.8% vs. 5.3% of total fatty acids; p < 0.001)

These outcomes persisted after adjusting for maternal age, BMI, parity, education, and zip-code–level socioeconomic indicators—suggesting nutritional optimization contributes meaningfully to perinatal equity. Importantly, registry participation remains high: 71% completed 6-month follow-up surveys, reflecting strong user trust and perceived value.

Testimonials highlight functional improvements beyond biomarkers. As shared in Veridia’s de-identified qualitative dataset (n = 1,043 open-ended responses), common themes included: “Less fatigue by week 8—I could walk my dog again without stopping,” “No more ‘prenatal breath’—my sense of smell normalized,” and “My nails stopped peeling at 14 weeks, and my hair shedding slowed dramatically.” While subjective, these reports align with known nutrient roles: iron for oxygen transport, zinc for olfactory receptor regeneration, and biotin + silica for keratin synthesis—all present in Adriti at evidence-supported doses (30 mcg biotin, 5 mg silica from horsetail extract).

Long-term neurodevelopmental tracking is underway: the ADAPT cohort is enrolled in the NIH’s ECHO Program, enabling linkage to standardized Bayley-4 assessments at 24 and 48 months. Preliminary 24-month data (n = 1,219) indicate children whose mothers used Adriti scored 4.2 points higher on the Cognitive Scale (mean 105.8 vs. 101.6; p = 0.007) and 3.7 points higher on the Language Composite (mean 104.1 vs. 100.4; p = 0.012) compared to matched historical controls—controlling for maternal education, household income, and breastfeeding duration.

Adriti represents a paradigm shift—not merely another prenatal vitamin, but a precision-tuned, rigorously validated tool for optimizing the foundational biology of human development. Its formulation bridges gaps between emerging science and everyday clinical practice, empowering providers and patients alike to act earlier, more confidently, and with greater impact. With continued investment in real-world evidence generation and equitable access expansion, Adriti is positioned to contribute meaningfully to national goals for reducing maternal mortality, preterm birth, and developmental disparities. As one participating CNM in rural Kentucky noted in the 2024 survey: “It’s the first prenatal I’ve recommended where I don’t need to add three other things—and my patients actually take it.”